Prognostic impact of RAS mutations in patients with myelodysplastic syndrome

Aref Al-Kali, Alfonso Quintás-Cardama, Raja Luthra, Carlos Bueso-Ramos, Sherry Pierce, Tapan Kadia, Gautam Borthakur, Zeev Estrov, Elias Jabbour, Stefan Faderl, Farhad Ravandi, Jorges Cortes, Ayalew Tefferi, Hagop Kantarjian, Guillermo Garcia-Manero

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


RAS is an oncogene frequently mutated in human cancer. RAS mutations have been reported in 10-15% of cases of acute myeloid leukemia (AML) but they appear to be less frequent among patients with myelodysplastic syndrome (MDS). The impact of RAS mutations in patients with MDS is unclear. We conducted a retrospective study in 1,067 patients with newly diagnosed MDS for whom RAS mutational analysis was available. Overall, 4% of patients carried mutant RAS alleles. Notably, FLT3 mutations, which were found in 2% of patients, were mutually exclusive with RAS mutations. Patients with RAS mutations had a higher white blood cell count as well as bone marrow blasts compared with patients carrying wild-type RAS. However, no differences were observed between both groups regarding the risk of AML transformation (9% vs. 7%) and overall survival (395 days vs. 500 days, P=0.057). In summary, RAS mutations are infrequent in patients with MDS and do not appear to negatively impact their outcome.

Original languageEnglish (US)
Pages (from-to)365-369
Number of pages5
JournalAmerican journal of hematology
Issue number5
StatePublished - May 2013

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Prognostic impact of RAS mutations in patients with myelodysplastic syndrome'. Together they form a unique fingerprint.

Cite this